Both NIV and HFNC are used to treat patients with acute respiratory failure. Current guidelines recommend NIV for acute respiratory failure caused by COPD and acute cardiogenic pulmonary edema. However, NIV may be hard for some patients to tolerate. When compared to low-flow oxygen therapy, HFNC has been shown to improve oxygenation, improve alveolar recruitment, and enhance clearance of secretions. HFNC may be easier to use and tolerate than NIV, but there remains uncertainty regarding the effectiveness of HFNC compared to NIV for acute hypoxemic respiratory failure. In this podcast, we discuss the RENOVATE trial that sought to compare HFNC with NIV on rates of intubation in patients with acute respiratory failure.
As we gain more experience managing critically ill patients with COVID-19 infection there has been a shift away from immediate intubation and towards more...
In this podcast we discuss the very controversial SSC 2018 Update. We know that sepsis is a time-sensitive illness, but does a 1-hour bundle...
The period following ROSC from cardiac arrest is a time when lives can be saved…or lost. A systematic and comprehensive approach to post-arrest care...